^
    1d
    AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P3, N=940, Recruiting, Novartis Pharmaceuticals | N=605 --> 940 | Trial primary completion date: Feb 2028 --> Sep 2028
    Enrollment change • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)
    1d
    A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer (clinicaltrials.gov)
    P1, N=38, Recruiting, Alpha Fusion Inc.
    New P1 trial
    1d
    ANDROMEDA: Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma (clinicaltrials.gov)
    P2, N=107, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)
    7d
    Study of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Not yet recruiting, Molecular Partners AG
    New P1/2 trial
    15d
    Phase 1 trial of a novel antibody-targeted radiotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) (ACTRN12625001362482)
    P1, N=42, Not yet recruiting, Actinium Pharmaceuticals Australia Pty Limited
    New P1 trial
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ERBB3 positive
    |
    barecetamab (ISU104)
    16d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Recruiting, ARTBIO Inc. | Trial completion date: Sep 2033 --> Nov 2028
    Trial completion date
    |
    AB001
    16d
    Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Institut Cancerologie de l'Ouest
    New P1 trial • First-in-human
    |
    Rencarex (girentuximab)
    20d
    Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001. (PubMed, Sci Rep)
    Total cell-bound activity, rather than added activity, better predicted radiotoxicity in both TP53-wild-type and TP53-null cell lines, indicating that its therapeutic effect is primarily governed by PSMA-mediated uptake rather than p53 status. These results support the therapeutic potential of [212Pb]Pb-AB001 across cells with varying TP53 status and suggest that combining [212Pb]Pb-AB001 with DNA repair or checkpoint inhibitors may enhance treatment efficacy.
    Journal
    |
    TP53 (Tumor protein P53) • FOLH1 (Folate hydrolase 1)
    |
    TP53 wild-type • FOLH1 expression
    |
    AB001
    23d
    Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. (PubMed, Pharmaceuticals (Basel))
    Early results support α-PRRT as a potential first- or second-line therapeutic option. Ongoing phase III trials will be critical to confirm its long-term safety, survival outcomes, and role in routine clinical practice.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    VMT-𝛼-NET
    23d
    ATLAS: Actinium Therapy for Late-stage Aggressive Sarcomas (clinicaltrials.gov)
    P1, N=26, Recruiting, Ratio Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    28d
    First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. (PubMed, ESMO Open)
    MSLN-TTC showed good tolerability, but the maximum tolerated dose could not be determined due to discontinuations after antidrug antibody formation. Stable disease was observed in 12 out of 36 patients.
    P1 data • Journal • First-in-human
    |
    MSLN (Mesothelin)
    |
    thorium (227Th) anetumab corixetan (BAY 2287411)
    28d
    Rad2Nivo: Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, University of Utah | Trial primary completion date: Jul 2025 --> Feb 2025
    Trial primary completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • Xofigo (radium Ra-223 dichloride)